This report was first published by Endpoints News. To see the original version, click here
A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives’ experiences at BioMarin.
The Bay Area startup, called Mendra, unveiled on Wednesday morning with a Series A that was co-led by OrbiMed, 8VC and 5AM Ventures. CEO Joshua Grass has been a venture partner at 5AM for the past year and was a 15-year BioMarin veteran. Lux Capital and Wing VC also took part in the round.
您已阅读13%（572字），剩余87%（3987字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。